Search Bar & Filters
Found 294 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.
Actively Recruiting
Researchers are studying calderasib alone and in combination with cetuximab to treat advanced solid tumors in people with the KRAS G12C mutation. The study aims to find out how many patients respond to these treatments and to evaluate their safety and tolerability. This phase 2 trial is tumor-agnostic, meaning it includes various solid tumors except colorectal cancer that have progressed despite standard treatment. Participants receive calderasib by mouth, either alone or with cetuximab given by intravenous infusion every two weeks. There is no set maximum number of treatment cycles, and participants continue until they meet criteria to stop treatment. The study is randomized and open-label, comparing the two treatment approaches in parallel groups. During the study, participants will be monitored for tumor response, adverse events, and reasons for discontinuing treatment over about 76 months. Researchers will assess progression-free survival, duration of response, and overall survival. Safety evaluations and regular clinical visits will support ongoing monitoring throughout the trial.
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
Actively Recruiting
Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.
Actively Recruiting
Researchers are evaluating new treatment approaches for advanced ovarian cancer in people whose tumors are non-HRD positive. This study aims to find out if adding sacituzumab tirumotecan sac-TMT, a targeted therapy, as maintenance treatmentwith or without bevacizumabhelps patients live longer without their cancer worsening compared to standard care. This is a phase 3 randomized study involving participants who have completed surgery and first-line platinum-based chemotherapy. Participants receive sac-TMT intravenously on days 1, 15, and 29 of every 6-week cycle until their disease worsens or they experience prohibitive side effects. Some may also receive bevacizumab intravenously on days 1 and 22 every 6 weeks for up to 22 cycles, depending on the investigators choice. The comparison group receives either bevacizumab alone on the same schedule or is observed closely without maintenance treatment. During the study, participants will have regular evaluations to monitor their cancer status and quality of life. Researchers will measure progression-free survival for up to about 49 months and assess overall survival, adverse events, treatment discontinuation, and changes in quality of life scores for up to 78 months. Participants health will be followed long-term to understand treatment effects and safety over time.
Actively Recruiting
Researchers are investigating metastatic colorectal cancer mCRC patients who have a specific genetic change called the BRAFV600E mutation. This rare subtype of mCRC often shows poor response to current treatments and has a generally poor outlook. The study aims to collect detailed clinical data and biological samples to better understand this condition, including how patients respond to treatments and what factors predict their survival. It focuses on real-world treatment outcomes and biological markers that might influence therapy choices and resistance. Participants will provide blood samples at multiple times during their treatment, including before and during the first three treatment cycles, at 3 and 6 months after starting each treatment line, and when disease progression occurs following certain therapies. The study gathers up to 390 mL of blood per participant over time to analyze circulating tumor DNA and immune environment factors. This observational approach will help researchers identify biomarkers related to treatment response and disease progression. During the study, participants clinical progress and survival will be tracked for up to five years. Researchers will review overall survival from diagnosis to death and assess how prognostic markers relate to progression-free survival and response to treatments. The study involves collecting tumor tissue samples and blood tests, along with routine follow-up visits. All data collected will contribute to understanding BRAFV600E mCRC and improving future treatment strategies.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are conducting a long-term observational study called POS-ARI-PC to understand acute respiratory infections ARI in adults and children who visit primary care facilities across Europe. The study aims to describe how ARI presents and is managed, including infections caused by known and emerging respiratory pathogens. It also seeks to build a research infrastructure to support future clinical studies on the treatment, diagnosis, and prevention of ARI in primary care. The study includes two main protocols POS-ARI-PC AUDIT and POS-ARI-PC CORE. The AUDIT protocol collects anonymous annual data from about 2,000 patients with ARI across Europe to describe patient presentations and care. The CORE protocol is a prospective observational study where patients with ARI undergo specific sampling and are followed for 28 days to capture infection causes and clinical outcomes. Embedded studies, such as POS-ARI-PC-001 focused on respiratory infections in older adults, are added to this platform with detailed appendices. Participants provide consent and complete questionnaires about their symptoms and experiences. They give combined throat and nose swabs for infection analysis and complete daily diaries for up to 14 days. Follow-up after 28 days collects information on consultations and hospital referrals. Some participants may join optional interviews to share their views. Researchers measure outcomes including illness severity, recovery, medication use, complications, and variations in care, aiming to improve understanding and readiness for future trials. The study runs until August 2027.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are conducting a prospective, multicenter cohort study to follow children with idiopathic nephrotic syndrome INS, a rare kidney disease. The study aims to collect data on pediatric patients treated by pediatric nephrologists in France and its overseas territories to better understand the diseases characteristics and support future clinical trials. The study involves regularly recording medical, biological, psychological, and social data through routine clinical follow-ups, hospitalizations, and consultations. Additionally, annual telephone interviews will be conducted for patients in remission. Quality of life, treatment adherence, and treatment impact questionnaires will also be collected. A biobank is established to collect blood, urine, hair, and nail samples at the disease onset before immunosuppressive treatment begins. Participants will be followed from disease onset until age 18 or transfer to adult nephrology care. Data is collected via a secure website, medically validated and entered by clinical research staff. The main outcome is the number of cases included and their characteristics over two years. Participation involves routine care visits, interviews, and questionnaires, with continued monitoring planned through the study period ending in 2048.
1-10 of 294
1